Short Takes

Document Sample
Short Takes Powered By Docstoc
					                                                                                                                               www.renalandurologynews.com        JUNE 2010     Renal & Urology News 9




                                                  News in Brief
                 Please visit us at www.renalandurologynews.com for the latest news updates from the fields of urology and nephrology



                                                      Short Takes                                                        Anti-Rejection Therapies
Vitamin B Could
Have a Down Side
                                                                           Kharasch, MD, PhD, and co-investiga-
                                                                           tors at Washington University School
                                                                                                                         Carry Similar Cancer Risks
Patients with diabetic nephropathy                                         of Medicine in St. Louis, Mo., found
should avoid taking high doses of B
vitamins to lower homocysteine levels,
                                                                           large amounts of the aquaporin-1
                                                                           and adipophilin proteins in urine
                                                                                                                         T   he increased risk of cancer among renal transplant patients is similar across
                                                                                                                             various immunosuppressant therapies, according to an Australian study
                                                                                                                         published online in the Journal of the American Society of Nephrology.
Canadian researchers reported in                                           samples of kidney cancer patients.            Martin P. Gallagher, MBBS, FRACP, of The George Institute for International
the Journal of the American Medical                                        Urine levels of these proteins were           Health in Camperdown, New South Wales, and collaborators followed 481 renal
Association (2010;303:1603-1609).                                          significantly greater in patients with         transplant recipients for a median of 20.6 years after they were randomized to
They studied 238 patients with type 1                                      clear cell or papillary cancers
                                                                                                                         receive azathioprine and prednisolone (group 1), cyclosporine monotherapy
                                                                                                                         (group 2), or cyclosporine monotherapy, with a switch to azathioprine and
or type 2 diabetes and diabetic neph-                                      than in patients with renal cancer
                                                                                                                         prednisolone after three months (group 3). At least one cancer developed
ropathy, randomly assigning subjects                                       of nonproximal tubule origin, control
                                                                                                                         in 226 participants. The mean times to the diagnosis of the first cancer were
to receive vitamin B (a single tablet                                      surgical patients, or healthy volun-          similar among the three groups (16, 15.3, and 15.7 years to the first non-skin
containing folic acid, vitamin B6, and                                     teers, according to an online report          cancer for groups 1, 2, and 3, respectively, and 13.6, 14.3, and 15.2 years to
vitamin B12) or placebo. At 36 months,                                     in Mayo Clinic Proceedings.                   the first skin cancer).
renal function declined by a mean of
16.5 mL/min/1.73 m2 in the vitamin                                         Severe Prostatitis Linked
B group compared with 10.7 mL/
min/1.73 min2 in the placebo recipi-
                                                                           To Periodontitis
                                                                           Men with the most severe form of
                                                                                                                         Red Meat Lovers May Have
ents.. In addition, the 36-month risk
of the composite outcome of heart
                                                                           prostatitis also showed signs of perio-
                                                                           dontitis, raising the possibility that the
                                                                                                                         Higher Bladder Cancer Risk
attack, stroke, revacularization, and                                      inflammation characterizing the two
all-cause mortality was twice as high in
the vitamin as in the placebo group.
                                                                           conditions may be related. In an online
                                                                           report published in the Journal of Peri-
                                                                                                                         A    12-year study of 1,762 individuals found that the risk of bladder cancer is
    
				
DOCUMENT INFO
Shared By:
Stats:
views:3
posted:7/24/2010
language:
pages:2
Description: A global leader in serving libraries of all types, ProQuest LLC (“ProQuest”) supports the breadth of the information community with innovative discovery solutions that power the business of books and the best in research experience. More than a content provider or aggregator, ProQuest is an information partner, creating indispensable research solutions that connect people and information. Through innovative, user-centered discovery technology, ProQuest offers billions of pages of global content that includes historical newspapers, dissertations, and uniquely relevant resources for researchers of any age and sophistication—including content not likely to be digitized by others.
BUY THIS DOCUMENT NOW PRICE: $6.95 100% MONEY BACK GUARANTEED
PARTNER ProQuest LLC
ProQuest creates specialized information resources and technologies that propel successful research, discovery, and lifelong learning.